What did the CQC actually change in March 2026?
Nothing changed in law; what happened on 26 March 2026 is that the CQC updated its scope-of-registration guidance to state explicitly that a service offering only diagnosis of ADHD or autism, with no treatment, does not need to register. The regulator's reasoning is now in black and white on its regulated activities pages: it does not consider the diagnosis of ADHD or autism to be treatment of disease, disorder or injury, and diagnosis does not fall within diagnostic and screening procedures either, because it involves no equipment measuring physiological data. A clinic that prescribes, titrates or otherwise treats remains squarely within scope and must be registered.
The position already existed: a parliamentary answer in March 2025 stated that providers offering only ADHD diagnosis, without any form of treatment, were not within scope of CQC registration as the regulations stood. What the March 2026 update did was remove the ambiguity that had let the sector, and some of its critics, talk past each other, and in doing so it put the regulatory gap on the record in the regulator's own words.
That gap is now the live policy question. The Independent Healthcare Provider Network has pushed back hard on the "unregulated private clinics" framing, correctly noting that providers delivering treatment are regulated and that many carry additional quality accreditation, while simultaneously backing the ADHD Taskforce's calls for regulation that is transparent and clear. Read those two positions together and the direction of travel is visible: the diagnosis-only exemption is unlikely to survive the decade unrevised, and providers structuring themselves around it are building on ground the policy debate has already marked for review.
Why is remote stimulant prescribing under fire?
Because the clinical corner-cutting alleged is specific, checkable and aimed at children. Reporting in February 2026 carried warnings from doctors that some national online providers had prescribed stimulants to children without a single in-person examination, including to young patients with potential underlying heart conditions, and health authorities in Greater Manchester responded by overhauling local rules to mandate face-to-face physical checks for children before treatment. The clinical anchor for the criticism is not new: NICE guidance requires a full physical assessment before stimulant treatment begins, including cardiovascular history and examination, and stimulants are Schedule 2 controlled drugs whose prescribing carries the corresponding weight.
"The criticism is not that remote ADHD care is illegitimate; it is that a fully remote pathway cannot discharge a requirement that includes a physical examination unless it deliberately builds the physical leg in."
That is a solvable design problem, with solutions ranging from arranged in-person checks through community partnerships to documented baseline observations, and the providers who solved it before February 2026 are the ones the coverage did not name. The providers who treated the physical assessment as a checkbox that videoconferencing could wave through are the reason regional commissioners are now writing their own rules, and regionally fragmented prescribing rules are a worse operating environment for everyone than the national clarity the sector should have insisted on itself.
For the dispensing side, the same scrutiny arrives one step downstream: a pharmacy dispensing Schedule 2 stimulants against a remote provider's private prescriptions is lending its registration to that provider's clinical governance, and the prescriber-verification bar covered in our forthcoming Schedule 2 remote dispensing guide should be read with this February's reporting in mind.
What is Right to Choose actually doing to the market?
Right to Choose has become the sector's demand engine and its reputational battleground at once. The mechanics are straightforward: patients in England referred for a first specialist appointment can choose any provider holding a qualifying NHS contract, and with standard NHS ADHD waits running to years, in some areas reportedly five or more, referral volume has flooded toward independent providers quoting months instead. Major providers have been quoting initial assessment waits measured in months and expanding clinical teams to absorb the inflow, while some pause referrals when capacity fills.
Three structural consequences follow for operators. First, the qualifying-contract gate does real work: Right to Choose eligibility requires a contract with an NHS commissioner, with accreditation demonstrating CQC-registered standards and NHS Standard Contract compliance, so the NHS-funded segment of this market is closed to the casually assembled. Second, local specification fragmentation is a genuine operating cost, since a provider serving patients across England may face dozens of differing commissioner specifications, which is why the sector's own representatives are lobbying for a single consistent service specification. Third, shared care is the choke point: a diagnosis and titration completed by a remote provider still needs a GP willing to take on prescribing under shared care, GP confidence is exactly what the February reporting damaged, and every provider's shared-care acceptance rate is now a commercial metric whether they measure it or not.
Layer the ongoing stimulant supply problems over all of this, with shortages across major ADHD lines tracked throughout 2025 and 2026 and Schedule 2 rules limiting the flexibility pharmacies have when stock fails, and the patient experience the sector is being judged on is only partly within any single provider's control. The operational playbook for the pharmacy end of that problem is our forthcoming guide to handling ADHD prescriptions in 2026.
What should serious providers build now?
Build as if the diagnosis-only exemption were already closed, the physical assessment were already mandated nationally and every shared-care GP were reading your titration records, because all three are where the pressure is pointing and none is expensive compared with retrofit. Concretely, four moves.
Register for what you actually do, and structure for what you will do. A service with any treatment ambition belongs inside CQC registration from the start, and the clinical-entity-plus-pharmacy architecture that carries assessment, titration and dispensing under coherent governance is a design exercise, covered in the clinic-plus-pharmacy model, not an afterthought.
Build the physical-health leg into the remote pathway. Documented baseline physical assessment including cardiovascular check before any stimulant is initiated, by whatever combination of in-person provision and verified local arrangements the model supports, with the evidence held per patient. Greater Manchester has shown what commissioners do when providers leave this to goodwill.
Make titration auditable. Structured dose records, scheduled reviews, monitoring observations captured over time and a record a shared-care GP can actually read are the difference between a titration service and a prescription subscription, and they are also precisely the records an inspector or a coroner asks for. The systems layer for this is the subject of our forthcoming piece on the IT gap in ADHD and titration services.
Treat the dispensing relationship as governance, not logistics. Whoever dispenses your Schedule 2 prescriptions is part of your clinical safety case: prescriber verification, private controlled drug prescription formalities and delivery assurance all sit downstream of the clinic and reflect straight back onto it.
Key takeaways
- The CQC's 26 March 2026 guidance update confirmed, in the regulator's own words, that diagnosis-only ADHD and autism services fall outside registration, while any service providing treatment remains fully in scope.
- The change is a clarification of an existing position, not new deregulation, and it has put the diagnosis-only gap squarely into a policy debate the ADHD Taskforce and sector bodies are already having.
- February 2026 reporting on remote stimulant prescribing to children without physical examination triggered mandatory face-to-face rules in Greater Manchester and put the NICE physical-assessment requirement at the centre of scrutiny.
- Right to Choose is the demand engine, gated by qualifying NHS contracts and fragmented local specifications, with shared-care acceptance now a commercial metric.
- Stimulants are Schedule 2 controlled drugs in intermittent shortage, which constrains every pathway downstream of the prescription.
- Serious providers should register for what they do, build the physical-health leg into remote pathways, make titration auditable and treat their dispensing partner as part of their governance.
- The likely direction is more codification, not less, so building above today's minimum is the cheap option.
FAQs
Built for scrutiny.
The pharmacy side of an ADHD service is exactly what Dataforge PMR runs: clinical assessments completed online with custom fields that let titration observations be updated and tracked over time, prescriber records and notes in one audit-trailed platform, reminders driving scheduled reviews, and dispensing with drug label printing, with a controlled drugs register module scheduled for release at the end of 2026. Our publisher also builds the compliant websites and market entry documentation behind services like these. If you are building or tightening an ADHD service, book a 30-minute call.
Book a call